Bmab 1300 (Adalimumab biosimilar)

About Biocon

Biocon's mission is to deliver affordable, high-quality biopharmaceuticals to a global patient population. The company has achieved global leadership in biosimilars, with multiple commercialized products in oncology, immunology, and diabetes, and has built a fully integrated platform from R&D to manufacturing. Its strategy is anchored in leveraging its deep bioprocessing expertise to expand its biosimilar portfolio, advance a pipeline of novel biologics, and grow its contract research and manufacturing services.

Therapeutic Areas